Abstract
To assess the incremental cost-effectiveness (ICER) and cost-utility (ICUR) ratio of polatuzumab vedotin with bendamustine and rituximab (Pola-BR) versus bendamustine and rituximab (BR) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not candidates for haematopoietic stem cell transplant (SCT), from the Italian Health Service perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
